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Summary: A sensitive fixed-time kinetic enzymatic method for the measurement of high density lipoprotein
cholesterol is described, äs adapted for the Cobas Bio centrifugal analyser (Hoffmann LaRoche). The
Boehringer Mannheim cholesterol esterase/cholesterol oxidase/peroxidase/3,4-dichlorophenol kinetic reagent
was modified by the inclusion of 2,4,6-tribromo-3-hydroxybenzoic acid which reacts with hydrogen peroxide
and 4-aminophenazone to produce a quinone-imine dye with a greater molar absorptivity than that produced
with phenol. The method has been developed for the detennination of HDL fractions isolated with polyethyl-
ene glycol 6000, for which a reagent of high sensitivity is required.
The method is linear to at least 3.88 mmol/1 of HDL cholesterol and the coefficients of Variation for within-
run and day-to-day precision were less than 3.0%. Correlation of the kinetic HDL cholesterol method with
an equilibrium method was good (R = 0.9980).
The ässay is rapid, inexpensive and large numbers of specimens can be processed conveniently.
Introduction
The analysis of high density lipoprotein cholesterol
has, in epidemiological and clinical studies (1^6),
shown that a low HDL cholesterol level üsually indi-
cates a risk for coronary heart disease. The increased
demand for HDL cholesterol assays had led to the
need for a method capable of handling large numbers
of assays generated frona clinical and epidemiological
workf The Boehringer Männheim cholesterol oxidase
4-aminophenazone (CHOD-PAP) reagent for cho-
lesterol has been adapted for use with a centrifugal
anälyser to measure HDL cholesterol "äs an equili^
brium method (7). The incorpQration of 3,4-dichloro-
phenol in the Boehringer Mannheim CHOD-PAP
reagent has enabled the assay of total serum choles-
terol üsing automated fixed-time kinetic methodology
(8). The kinetic cholesterol method has coüsiderably
reduced the analytical time require4 therefore allow-
ing more efficient use of automated instruments, and
has the advantage of being less sensitive to interfer-
ences than are equilibrium methods.
However, the adaptation of the kinetic method for
the analysis of HDL cholesterol would involve the
measurement of significäntly smaller absorbance dif-
ferences ( ). Since a relatively high photometric
error would be incurred in the measurement of such
low absorbance values (9), the assay was modified by
adding i^o^tribromo-S-hydroxybenzoic acid to the
Boehringer Mannheim kinetic cholesterol reagent.
The tribromohydroxybenzoic acid reacts with hydro-
gen peroxide and the 4-aminophenazone/peroxidase
System to produce quantitative amounts of quinone-
imine dye. Details of the modified assay are reported.
Materials and Methods
Apparatus
Cobas Bio centrifugal analyser (F. Hoflfman-La Röche and Co.,
Limited Company, Basle, Switzerland) and related accessories.
Hettich Universal K2S refrigerated centrifuge (Andreas Het-
tich, 1\ittiingen, W. Germany).
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Reagents
Buffercd polyethylene glycol 6000: Polyethylene glycol, average
relative molecular mass Mr = 6000 (British Drug Houses) 200
g/l in glycine/NaOH buffer, 0.2 mol/1, pH 10.
2,4,6-Tribromo-3-hydroxybenzoic acid: Synthesised by bromi-
nation of Analar grade 3-hydroxybenzoic acid (10).
Cholesterol reagenl: Boehringer Mannheim "CHOD-PAP" ki-
netic colorimetric test (catalogue number 692905).
Cholesterol Standards: Preciset® High Performance Standards
(Boehringer Mannheim, GmbH catalogue number 709905).
High Density Lipoprotein Cholesterol Controi: Boehringer
Mannheim Precinorm®L (lyophilised) catalogue number
781827, lot number 154747.
Procedures
Isolation of HDL
Buffered polyethylene glycol 6000 solution (0.2 ml) was mixed
with plasma (0.2 ml). After 10 min at 20 — 25 °C, the mixture
was centrifuged at 2000 g for 20 min at 4 °C. The supernatant
was aspirated for cholesterol analysis. Positive displacement
pipettes were used for all quantitative pipetting procedures.
Cobas Bio reagent boat
Equal quantities of 9 g/l NaCl solution and polyethylene glycol
6000 solution were mixed and placed in Standard well l. Cho-
lesterol Standards were mixed with equal quantities of polyetr>
ylene glycol 6000 solution. Boehringer Mannheim Preciset Stan-
dard 1.29 mmol/1 was placed in Standard well 2, and Standard
2.59 mmol/1 in well 3. For 70 assays, the reconstituted CHOD-
PAP reagent (25 ml) was combined with 2,4,6-tribromo-3-
hydroxybenzoic acid and placed in the main well. This reagent
was discarded after use. Various concentrations of 2,4,6^tri-
bromo-3-hydroxybenzoic acid ranging from 0—20 mmol/1 were
evaluated to determine the most suitable strength.
Cobas Bio procedure
Various plasma/reagent ratios were tried in a series of prelimi-
nary experiments and the most suitable was found to be l to
55. This ratio and the Optimum 2,4,6-tribromo-3-hydroxyben-
zoic acid concentration was a compromise to obtain the desired
sensitivity required for a rapid kinetic method. The maximum
absorbance of the quinone-imine dye, which represents the final
product of the reaction, was at 515 nm. Absorbances measured
in this region are less likely to be affected by colorimetric
interference due to haemolysed or icteric plasmas. The instru-
ment was operated according to the settings listed in table I.
Results
Concentration of 2,4,6-tribromo-3-hy-
droxybenzoic acid
The concentration of 10 mmol/1 2,4,6-tribromo-3-
hydroxybenzoic acid in the Boehringer Mannheim
reagent produced the largest absorbance differences
(ΔΑ) for a total reaction time of 50 seconds. These
absorbance differences obtained using 2,4,6-tribro-
mo-3-hydroxybenzoic acid were three times greater'
Tab. 1. Parameter listing for determination of high density
lipoprotein cholesterol on the Cobas-Bio centrifugal
analyser by the fixed-time kinetic method.
Units mmol/1
Calculation factor
Standard l conc.
Standard 2 conc.
Standard 3 conc.
Limit (mmol/1)
Temperature °C
Type of analysis
Wavelength (nm)
Sample Volume (ul)
Diluent Volume (μΐ)
Reagent Volume (ul)
Incubation time (s)
Start reagent volume (μΐ)
Time of First Reading (s)
Time intervai (s)
Number of Readings
Blank mode
0.0 (Polyethylene glycol blank)
1.29 , ,
2.59
4.0
30
5
515
15
30
350
30
0
10
10
6
l (reagent blank)
than those produced with phenol alone in the un-
modified CHOD-PAP kinetic cholesterol reagent (fig.
1). Subsequent work was carried out using 10 mmol/1.
2,4,6-tribromo-34iydroxybenzoic acid.
Course of the reaction
The feasibility of an assay protocol based on first-
order kinetics was examined by following the progiress
c rve of four aqueous cholesterol Standards (0.65,
1.29, 2.59 and 3.88 mmol/1) and two patient plasmas
(0.80 and 1.95 mmol/1 HDL eholesterol), all treated
with polyethylene glycol. The semilogarithmic plot of
absorbance at completion of reaction minus absorb-
ance at time t versus t indicates that the reaction
follows first-order kinetics since the plot is linear
from 10 seconds to at least four min tes (fig. 2). The
initial lag phase is terminated within the first 10
seconds of the reaction. A total reaction time of
60 seconds provides sufficient linearity and a short
analysis time. Therefore, the subsequent kinetic pro-
tocol was based on the preineubation of the 2,4,6-
tribromo-3-hydroxybenzoic acid modified reagent at
30 °C for 30 seconds, the absorbance difference toeing
calculated from the difference between the absorb-
ances at 60 seconds and 10 seconds after plasma and
reagent mixing (ΔΑ/50 seconds).
Linearity
l..;
Linearity was determined with the Preciset® choles-
terol Standards and their diltitions (fig. 3) and serial
dilutions of a patient plasma with a HDL cholesterol
value of 2.45 mmol/1 (fig. 4). The linear r nge for the
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Standards was from at least 0.25 to 3.88 mmol/1. The
ΔΑ values for the dilutions of the patient plasma
were proportional within the dilution r nge tested
(l: l to l: 16). The linear r nge of the assay therefore
covers the majority of the population values likely to
be encountered (0.5 to 2.5 mmol/1) (7).
Accuracy and precision
Comparison of 48 patient HDL cholesterol plasma
values obtained for a fixed-time kinetic method (x)
and an equilibrium method (y) (7) showed good
correspondence of results (r = 9980, y = 1.01 Ix
+ 0.016) (fig. 5).
1
1.0
0.8
10.6
<c
<3
0.4
0.2
HD L-cholesterol
[mmol/U
\ >
0 5 10 15 20
2,4,6-Tribromo-3-hydroxybenzoic acid [mmol/l]
Fig. 1. Absorbance plots of HDL cholesterol Standards utilis-
mg varying concentrations of 2,4,6-tribroimo-3-hy-
droxybenzoic acid in the enzymic cholesterol reagent.
3.0
2.0
i v,
0 1 2 3 4
t Lmin]
Fig. 2. Urne course of reaction.
At, absorbance at time t; A^, absorbance after compte?
tion of reaction; rate constant, k = — ΔΙηζΑ^ — AJ/
At (slope of curves). Specimens: l, 3, 5, 6, Preciset
Cholesterol'high performance (0.65, 1.29, 2.59, 3.88
mmol/1, respectively); 2, 4, human plasma (0.85, 1.99
mmol/1 HDL cholesterol, respectively).
1.0
0.8
I 0.6
0.4
Q.2
1:0 2.0 3.0
HDL-cholesterol [mmol/1]
4.0
Fig. 3. Linearity of the fixed-time kinetic HDL cholesterol as-
say utilising 10 mmol/1 2,4,6-tribromo-3-hydroxyben-
zoic acid in the enzymic cholesterol reagent (duplicate
assay s).
0.5
0.4
0.3
<3
0.2
0.1
1:16-1:8 1:4 1:2
Sample dilution
1:1
(undiluted)
Fig. 4. Linearity of the fixed-time kinetic HDL cholesterol as-
say on serial dilutions of a human plasma containing
2.45 mmol/1 HDL cholesterol (duplicate assay s).
3.0
2.0
S 1.0
31
 0 1.0 2.0 3.0
HOL-cholesterol (fixed-time kinetic method)
[mmol/l]
Fig. 5. Comparison of an equilibrium method (y) and the fixed-
time kinetic HDL cholesterol method (x) in 48 human
plasmas (slope = 1.011, axis interccpt = 0.016 mmol/l,
correlation coefilcient - 0.9980).
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Multiple analysis of the precinorm® L control serum
produced mean values close to the manufacturer's
value of 1.14 mmol/1 (ränge = 0.96 to 1.32 mmol/1).
The within-run precision using Precinorm L was
represented by a coefficient of Variation of 2.0%
(x = 1.202 mmol/1, n = 20). The between-run preci-
sion was 2.6% (x = 1.180, n = 20). Analysis of a
plasma pool with a low concentration of HDL cho-
lesterol produced within-run and between-run coeffi-
cients of Variation of 1.4% (x = 0.6763, n = 20) and
2.9% (x = 0.6902, n = 20) respectively. The within-
run and between run precision of a plasma pool with
a high concentration of HDL cholesterol were 1.1%
(x = 1.6988, n = 20) and 1.6% (x = 1.7234, n = 20)
respectively.
Interferences
The results of interferences by drugs, plasma metab-
olites or coloured constituents of blood are repre-
sented in table 2. Concentrations of the substances
examined Were added to a pooled specimen of human
plasma. This plasma pool had a HDL cholesterol
value of 1.24 mmol/1 (mean of 10 assays) in the
absence of any added substance.
Tab. 2. Interference of added substances (plasma concentra-
tions of drugs usually found after administration of
therapeutic doses in brackets).
Substances added, final concentration Percentage of
HDL cholesterol
accounted for
Urea, 200 mg/1
Creatinine, 100 mg/1
Uric acid, 200 mg/1
Glucose, 4000 mg/1
Bilirubin, 50 mg/1
Bilirubin, 100 mg/1
Haemoglobin, 1000 mg/1
Haemoglobin, 2000 mg/1
Salicylate, 1000 mg/1 (200 mg/1)
Gentisic acid, 30 mg/1 (l mg/1)
Gentisic acid, 50 mg/1
L-Dopa, 5 mg/1 (l mg/1)
L-Dopa, 10 mg/1
a-Methyldopa, 30 mg/1 (l mg/1)
a-Methyldopa, 50 mg/1
Ascorbic acid, 20 mg/1 after 0 h
Ascorbic acid, 50 mg/1 after 0 h
Ascorbic acid, 20 mg/1 after l h
Ascorbic acid, 50 mg/1 after l h
Ascorbic acid, 20 mg/1 after 2 h
Ascorbic acid, 50 mg/1 after 2 h
Ascorbic acid, 20 mg/1 after 3 h
Ascorbic acid, 50 mg/1 after 3 h
at 20 °C
at 20 °C
at 20 °C
at 20 °C
at 20 °C
at 20 °C
at 20 °C
at 20 °C
99
99
99
98
99
98
98
97
101
94
90
90
86
79
71
84
63
93
81
95
90
99
97
Discussion
The kinetic fixed-time techniqüe for enzymatic ana-
lysis of total serum cholesterol was made possible by
the use of cholesterol oxidase from a Streptomyces
species instead of the enzyme from Nocardia erythro-
polis (8). The Michaelis constant (Km) with respect to
cholesterol of the Streptomycti enzyme can appar-
ently be increased, by adding the competitive iiihibi-
tor, 3,4-dichlorophenol, to such an extent that the
cholesterol oxidase reaction would follow first-order
kinetics over a large ränge of cholesterol concentra-
tions. By exploiting this Inhibition, together with the
very efficient cholesterol esterase, a kinetic cholesterol
reagent was developed. In this kinetic System, the
cholesterol oxidase reaction is the rate limiting step,
so that the indicator reaction follows first-order kine-
tics (Boehringer Mannheim catalogue riumber
692 905 and 725 242).
Addition of 2,4,6-tribromo-3-hydroxybenzoic acid to
this reagent to enhance the indicator reaction pro*
duces an increase in the sensitivity with respect to
cholesterol so that a kinetic protocol mäy also be
used to measure HDL cholesterol. Compared with
the unmodified reagent, the method described in this
report enables a three-fold increase in the absorbance
differences ( ) of HDL cholesterol supernatants
prepared with buffered polyethylene glycol 6000, a
procedure whieh involves a two-fold dilution of
plasma. The use of buffered polyethylene glycol 6000
to isolate HDL enables the Clearing of most lipaemic
plasmas which would otherwise cause an over-estiina-
tion of HDL cholesterol (11). The polyethylene glycol
6000 procedure is also äcourate and efficient (12).
Preliminary results also indicate that HDL süperna*
tants prepared by the phosphotungstic acid/MgCk
(13) or dextran sulphate 500/MgCl2 (14) ß-lipoprotein
precipitation methods may be assayed with the kinetic
method on the Cobas-Bio analyser provided that it
is programiiied with a sample volume of 7 , instead
of 15 1.
The first-order kinetics of the HDL cholesterol ki-
netic method show a parallelism among the aqueous
Standards and the patient plasmas (flg. 2), indicating
that the protocol described is suitable for routine
estimation of patient HDL cholesterol values. Corre-
lation between the kinetic and equilibrium methods
was excellent and there was good agreement between
the value obtained for the Precinorm® L control aiid
the manufacturer's value. Linearity and precision are
comparable to equilibrium methods (7,11).
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In contrast to the kinetic method for total serum
cholesterol (8), in vitro addition of large amounts of
substituted phenols such äs L-dopa, methyldopa and
gentisic acid to the plasma pool caused significant
interference. However, the concentrations that these
drugs attain in vivo would interfere negligibly (15).
Interference from added ascorbic acid was minimised
by leaving the HDL supernatant at room temperature
for three hours before analysis. Ascorbic acid in solü-
tion rapidly oxidises in the presence of oxygen, es-
pecially at pH > 7.0 (16). In any case, a normal
plasma ascorbic acid level of less than 20 mg/1 should
not interfere significantly and any higher levels due
to, excessive administration of vitamin C can be over-
come by extending to 3 hours the interval between
blood-taking and HDL cholesterol determination.
In conclusion, the present method involving 2,4,6-
tribromo-3-hydroxybenzoic acid addition to the
Boehringer Mannheim kinetic cholesterol reagent af-
fords a faster, convenient analysis of HDL cholesterol
than the corresponding equilibrium methods. Hence,
the method is suitable for routine use in the auto-
mated laboratory. The method is also relatively cheap
and has the potential of being used to measure the
cholesterol in LDL and HDL subfraction isolates
(HDL2 and HDL3).
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